At what enterprise value was AFFIDEA acquired in 2022?

During the acquisition of AFFIDEA by GROUPE BRUXELLES LAMBERT in 2022, the transaction's Enterprise Value is estimated to be in the range of €1–10bn.

What was the EV/EBITDA of AFFIDEA when it was acquired by GROUPE BRUXELLES LAMBERT?

The estimated EV/EBITDA multiple for AFFIDEA is in the range of 10x - 18x.

What was the EV/Revenue multiple of AFFIDEA when it was acquired by GROUPE BRUXELLES LAMBERT?

The estimated EV/Revenue multiple for AFFIDEA is in the range of 2x - 6x.

When was AFFIDEA acquired by GROUPE BRUXELLES LAMBERT?

AFFIDEA was acquired by GROUPE BRUXELLES LAMBERT in 2022.

What was the revenue of AFFIDEA at the time of the deal?

The revenue of AFFIDEA at the time of the deal is estimated to be in the range of €450–900M.

What was the EBITDA of AFFIDEA during the acquisition?

AFFIDEA's EBITDA is estimated to be in the range of €100–200M.

How is the data for the AFFIDEA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the AFFIDEA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://affidea.ch/fr/actualites/affidea-groupe-bruxelles-lambert/

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaAFFIDEA

04/2022

AFFIDEA acquired by GROUPE BRUXELLES LAMBERT

NETHERLANDS Health Providers / Outpatient Care / Radiology EV €1–10bn

Context

The Brussels Lambert Group (GBL) has finalized the acquisition of a majority stake in Affidea, the European leader in diagnostic imaging and outpatient care, from B-FLEXION (family office), which is exiting the investment after eight years. The transaction is structured as a secondary LBO in which the current management team has reinvested a significant portion of its proceeds alongside GBL to ensure alignment of interests. This buyout marks a major step in the strategic rotation of GBL's portfolio, significantly increasing its exposure to private assets at the expense of its historic listed holdings.

AFFIDEA, which reported an EBITDA margin of [members only] in 2021, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, representing a discount to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1991, Affidea is Europe's leading provider of diagnostic imaging, outpatient care, and oncology services. The group operates 320 centers in 15 countries, welcoming more than 10 million patients per year. It is recognized for its clinical excellence (more than 50% of its centers are “Eurosafe Star” certified in Europe).

Ent. Value

€1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

2x–6x

EV / EBITDA

10x–18x

EV / EBIT

[members only]

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2021

2020

Similar deals in Health Providers

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
06/2022	TRITON PARTNERS	ESPERI CARE	FINLAND	Nursing Homes
06/2022	EURAZEO	SEVETYS	FRANCE	Vet Clinics
02/2022	MEINE RADIOLOGIE	ALERIS - RADIOLOGY	SWEDEN	Radiology
02/2022	PARTNERS GROUP	Forefront Dermatology	UNITED STATES	Outpatient Care
01/2022	WREN HOUSE	VOYAGE CARE	UNITED KINGDOM	Nursing Homes
12/2021	VIVALTO PARTNERS / IK PARTNERS / MACSF / ARKEA CAPITAL / BNP PARIBAS DEVELOPPEMENT	VIVALTO SANTÉ	FRANCE	Clinics / Hospitals
12/2021	RAMSAY HEALTH CARE	ELYSIUM HEALTHCARE	UNITED KINGDOM	Clinics / Hospitals
11/2021	CERBA HEALTHCARE	LABEXA	FRANCE	Labs (Biology)
10/2021	THE CRANEMERE GROUP	OUTPATIENT IMAGING AFFILIATES	UNITED STATES	Radiology
10/2021	IVC EVIDENSIA	VETONE	FRANCE	Vet Clinics

REFERENCES

Valuation range: EV €1–10bn

Revenue range: €450–900M

EBITDA range: €100–200M

EV/Revenue range: 2x - 6x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of AFFIDEA by GROUPE BRUXELLES LAMBERT are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: affidea

Acquirer: groupe bruxelles lambert